Abaloparatide

阿巴帕肽

Report date: 2025/05/19 20:00:42
NME

Base Information

Drug NameAbaloparatide
Drug Alias NameAbaloparatide TD阿巴帕肽巴罗旁肽Synthetic human parathyroid hormone 37-70 analogueabaloparatide +[16] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionParathyroid hormone/parathyroid hormone-related peptide receptor agonists
TargetsParathyroid hormone/parathyroid hormone-related peptide receptor
Therapy Area/IndicationsOsteoporotic FracturesFractures, BoneIntervertebral Disc Degeneration +[5] 
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/04/28
Country/TerritoryCzechiaUnited StatesPoland +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesIpsen
China Registration ClassN/A

Develop Information

Active CompaniesPharmanoviaTeijin PharmaWeill Medical College of Cornell University +[13] 
Inactive CompaniesRadius International LtdJohns Hopkins University
Active IndicationsFractures, BoneOsteoporosis, PostmenopausalOsteoporosis
Inactive IndicationsOsteoporotic FracturesIntervertebral Disc Degeneration

Other Information

ATC CodeH05AA
Related LinksWikipediaDrugBankKEGG